Abstract：
KRAS is the most frequently mutated oncogene in cancer and encodes a key signaling protein in tumors. Due to its high affinity for GTP and the lack of a large binding pocket that allosteric inhibitors can occupy, KRAS has long been considered \'non-druggable.\' Finding effective treatment measures for patients with KRAS mutations is our top priority.
In this article, we will provide an overview of the KRAS pathway and review the current state of therapeutic strategies for targeting oncogenic KRAS, as well as their potential to improve outcomes in patients with KRAS-mutant malignancies. We will also discuss the development of these strategies and gave an outlook on prospects.
KRAS mutations have posed a significant challenge in the treatment of advanced non-small cell lung cancer (NSCLC) over the past few decades. However, the emergence of immunotherapy and KRAS inhibitors, such as Sotorasib (AMG 510) and Adagrasib (MRTX849), has marked a new era in cancer therapy. As more research and clinical trials continue, we anticipate the development of more effective treatment strategies and better options for lung cancer patients.
In this article, we will provide an overview of the KRAS pathway and review the current state of therapeutic strategies for targeting oncogenic KRAS, as well as their potential to improve outcomes in patients with KRAS-mutant malignancies. We will also discuss the development of these strategies and gave an outlook on prospects.
KRAS mutations have posed a significant challenge in the treatment of advanced non-small cell lung cancer (NSCLC) over the past few decades. However, the emergence of immunotherapy and KRAS inhibitors, such as Sotorasib (AMG 510) and Adagrasib (MRTX849), has marked a new era in cancer therapy. As more research and clinical trials continue, we anticipate the development of more effective treatment strategies and better options for lung cancer patients.
摘要：
■KRAS是癌症中最常突变的癌基因，编码肿瘤中的关键信号蛋白。由于其对GTP的高亲和力以及缺乏变构抑制剂可以占据的大结合袋，KRAS长期以来被认为是不可下药的。为KRAS突变患者寻找有效的治疗措施是我们的首要任务。
■在本文中，我们将提供KRAS途径的概述，并回顾靶向致癌KRAS的治疗策略的现状，以及它们改善KRAS突变恶性肿瘤患者预后的潜力。我们还将讨论这些战略的发展，并对前景进行展望。
KRAS突变在过去几十年中对晚期非小细胞肺癌（NSCLC）的治疗提出了重大挑战。然而,免疫疗法和KRAS抑制剂的出现，如Sotorasib（AMG510）和Adagrasib（MRTX849），标志着癌症治疗的新时代。随着更多的研究和临床试验的继续，我们预计肺癌患者将有更有效的治疗策略和更好的选择.
■在本文中，我们将提供KRAS途径的概述，并回顾靶向致癌KRAS的治疗策略的现状，以及它们改善KRAS突变恶性肿瘤患者预后的潜力。我们还将讨论这些战略的发展，并对前景进行展望。
KRAS突变在过去几十年中对晚期非小细胞肺癌（NSCLC）的治疗提出了重大挑战。然而,免疫疗法和KRAS抑制剂的出现，如Sotorasib（AMG510）和Adagrasib（MRTX849），标志着癌症治疗的新时代。随着更多的研究和临床试验的继续，我们预计肺癌患者将有更有效的治疗策略和更好的选择.
